<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Saeed A</submitter><funding>NCATS NIH HHS</funding><funding>NHLBI NIH HHS</funding><pagination>105551</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11764641</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>112</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Preclinical data have shown that low levels of metabolites with anti-inflammatory properties may impact metabolic disease processes. However, the association between mid-life levels of such metabolites and long-term ASCVD risk is not known.&lt;h4>Methods&lt;/h4>We characterised the plasma metabolomic profile (1228 metabolites) of 1852 participants (58.1 ± 7.5 years old, 69.6% female, 43.6% self-identified as Black) enrolled in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study. Logistic regression was used to assess the impact of metabolite levels on ASCVD risk (nonfatal MI, revascularisation, and cardiac mortality). We additionally explored the effect of genetic variants neighbouring ASCVD-related genes on the levels of metabolites predictive of ASCVD e</pubmed_abstract><journal>EBioMedicine</journal><pubmed_title>Mid-life anti-inflammatory metabolites are inversely associated with long-term cardiovascular disease events.</pubmed_title><pmcid>PMC11764641</pmcid><funding_grant_id>R01 HL089292</funding_grant_id><funding_grant_id>R01 HL141824</funding_grant_id><funding_grant_id>R01 HL168683</funding_grant_id><funding_grant_id>UL1 TR001857</funding_grant_id><pubmed_authors>Duan J</pubmed_authors><pubmed_authors>Mapstone M</pubmed_authors><pubmed_authors>Reis SE</pubmed_authors><pubmed_authors>Vu M</pubmed_authors><pubmed_authors>Ballantyne CM</pubmed_authors><pubmed_authors>Lopez OL</pubmed_authors><pubmed_authors>McKennan C</pubmed_authors><pubmed_authors>Finegold D</pubmed_authors><pubmed_authors>Cohen A</pubmed_authors><pubmed_authors>Yu B</pubmed_authors><pubmed_authors>Yang YN</pubmed_authors><pubmed_authors>Swanson J</pubmed_authors><pubmed_authors>Saeed A</pubmed_authors><pubmed_authors>Kip KE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mid-life anti-inflammatory metabolites are inversely associated with long-term cardiovascular disease events.</name><description>&lt;h4>Background&lt;/h4>Preclinical data have shown that low levels of metabolites with anti-inflammatory properties may impact metabolic disease processes. However, the association between mid-life levels of such metabolites and long-term ASCVD risk is not known.&lt;h4>Methods&lt;/h4>We characterised the plasma metabolomic profile (1228 metabolites) of 1852 participants (58.1 ± 7.5 years old, 69.6% female, 43.6% self-identified as Black) enrolled in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study. Logistic regression was used to assess the impact of metabolite levels on ASCVD risk (nonfatal MI, revascularisation, and cardiac mortality). We additionally explored the effect of genetic variants neighbouring ASCVD-related genes on the levels of metabolites predictive of ASCVD e</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2026-06-02T17:25:35.26Z</modification><creation>2025-04-19T18:20:05.833Z</creation></dates><accession>S-EPMC11764641</accession><cross_references><pubmed>39793479</pubmed><doi>10.1016/j.ebiom.2024.105551</doi></cross_references></HashMap>